A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
M.D. Anderson Cancer Center
Perspective Therapeutics
HiFiBiO Therapeutics
Seattle Children's Hospital
Seattle Children's Hospital
Tango Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Actym Therapeutics, Inc.
Medical College of Wisconsin
University of Pittsburgh
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Cancer Research UK
Columbia University
Instituto do Cancer do Estado de São Paulo
Mayo Clinic
Ipsen
University Hospital, Antwerp
Prelude Therapeutics
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Translational Research in Oncology
Institut Bergonié
Quadriga Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
MacroGenics
Emory University
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
NYU Langone Health
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Pediatric Brain Tumor Consortium